CagriSema is Novo Nordisk's fixed-combination cagrilintide + semaglutide obesity drug — the company's bid to push the GLP-1 efficacy ceiling higher by adding amylin biology on top of the GLP-1 backbone.
The REDEFINE-1 and REDEFINE-2 Phase 3 trials read out across 2025 and 2026. The February 23, 2026 head-to-head readout against tirzepatide was the inflection point: 23% mean weight loss on CagriSema 2.4/2.4 mg vs 25.5% on tirzepatide 15 mg over 84 weeks, missing the non-inferiority primary endpoint and dropping NVO 15% intraday. Novo's Q1 2026 disclosures (May 6) confirmed a higher-dose CagriSema Phase 3 trial will start in H2 2026, but also disclosed that the company has discontinued the single-chamber co-formulation device project 'due to portfolio considerations' — the dual-chamber injectable system continues, the original FDA filing has been submitted, and a decision is expected late 2026. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg and the Wegovy pill.
Stories here cover the REDEFINE readouts, the regulatory path, and the broader amylin-add-on field. See #cagrilintide for the amylin component and #amylin for class context.
Novo Nordisk confirmed in its Q1 2026 commentary that a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Phase 3 trial will start in the second half of 2026, in response to the February 23 readout where the lower-dose 2.4/2.4 mg arm achieved 23% mean weight loss vs. 25.5% on tirzepatide 15 mg over 84 weeks — failing the non-inferiority primary endpoint. The original CagriSema FDA filing is already submitted with a decision expected in late 2026; the higher-dose program is meant to position Novo for a more competitive head-to-head against tirzepatide before the retatrutide TRIUMPH readouts arrive. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg.
Novo Nordisk announced April 28 that it will present 52 abstracts at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), including new data from the REDEFINE 1 trial of CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg): body composition and muscle strength, achievement of BMI/waist-to-height ratio targets, and cardiovascular risk reduction. Additional presentations will cover higher-dose Wegovy (semaglutide 7.2 mg), the Wegovy pill (oral semaglutide 25 mg) from OASIS 4 and ORION trials, and obesity treatment outcomes in women. The disclosure sets up a significant amylin/GLP-1 combination data event exactly as Zealand and Roche's amylin-only petrelintide moves into Phase 3.
C&EN published a comprehensive April 2026 feature examining whether amylin analogs — Novo's cagrilintide, Lilly's eloralintide, and Roche/Zealand's petrelintide — can carve meaningful share in a market dominated by semaglutide and tirzepatide. Wall Street initially expected amylin candidates to differentiate on muscle preservation and reduced GI side effects, but as Phase 2 readouts arrive investor enthusiasm has cooled. CagriSema Phase 3 head-to-head against tirzepatide is the make-or-break readout for Novo Nordisk's amylin strategy.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.